The Novo Nordisk Foundation pledged up to $850 million to expand the BioInnovation Institute (BII) beyond Denmark and accelerate European life‑science startups. BII, spun out of the foundation, has supported 131 Danish startups to date; the new funding targets pan‑European deal flow, incubation, and translational support to boost early‑stage commercialization and scale‑up capacity. The commitment reflects continued philanthropic and mission‑driven capital deployments into biotech venture ecosystems, aiming to bridge pre‑seed and seed capital gaps and de‑risk nascent platform technologies. BII plans to deploy funding into company building, infrastructure and cross‑border partnerships. For founders and investors, the program could broaden access to institutionalized startup support across Europe and heighten competition for top translational projects.